204 related articles for article (PubMed ID: 37700438)
1. YTHDF2 promotes gallbladder cancer progression and gemcitabine resistance via m6A-dependent DAPK3 degradation.
Bai X; Chen J; Zhang W; Zhou S; Dong L; Huang J; He X
Cancer Sci; 2023 Nov; 114(11):4299-4313. PubMed ID: 37700438
[TBL] [Abstract][Full Text] [Related]
2. VIRMA contributes to non-small cell lung cancer progression via N
Xu Y; Chen Y; Yao Y; Xie H; Lu G; Du C; Cheng J; Zhou J
Cancer Lett; 2021 Dec; 522():142-154. PubMed ID: 34520821
[TBL] [Abstract][Full Text] [Related]
3. ELF3 promotes gemcitabine resistance through PKMYT1/CDK1 signaling pathway in gallbladder cancer.
Yang L; Wang H; Guo M; He M; Zhang W; Zhan M; Liu Y
Cell Oncol (Dordr); 2023 Aug; 46(4):1085-1095. PubMed ID: 36988891
[TBL] [Abstract][Full Text] [Related]
4. Gene amplification-driven RNA methyltransferase KIAA1429 promotes tumorigenesis by regulating BTG2 via m6A-YTHDF2-dependent in lung adenocarcinoma.
Zhang C; Sun Q; Zhang X; Qin N; Pu Z; Gu Y; Yan C; Zhu M; Dai J; Wang C; Li N; Jin G; Ma H; Hu Z; Zhang E; Tan F; Shen H
Cancer Commun (Lond); 2022 Jul; 42(7):609-626. PubMed ID: 35730068
[TBL] [Abstract][Full Text] [Related]
5. YTHDF2 mediates the mRNA degradation of the tumor suppressors to induce AKT phosphorylation in N6-methyladenosine-dependent way in prostate cancer.
Li J; Xie H; Ying Y; Chen H; Yan H; He L; Xu M; Xu X; Liang Z; Liu B; Wang X; Zheng X; Xie L
Mol Cancer; 2020 Oct; 19(1):152. PubMed ID: 33121495
[TBL] [Abstract][Full Text] [Related]
6. Activation of the KDM5A/miRNA-495/YTHDF2/m6A-MOB3B axis facilitates prostate cancer progression.
Du C; Lv C; Feng Y; Yu S
J Exp Clin Cancer Res; 2020 Oct; 39(1):223. PubMed ID: 33087165
[TBL] [Abstract][Full Text] [Related]
7. RNA N6-methyladenosine methyltransferase-like 3 promotes liver cancer progression through YTHDF2-dependent posttranscriptional silencing of SOCS2.
Chen M; Wei L; Law CT; Tsang FH; Shen J; Cheng CL; Tsang LH; Ho DW; Chiu DK; Lee JM; Wong CC; Ng IO; Wong CM
Hepatology; 2018 Jun; 67(6):2254-2270. PubMed ID: 29171881
[TBL] [Abstract][Full Text] [Related]
8. The m6A Reader YTHDF2 Promotes Bladder Cancer Progression by Suppressing RIG-I-Mediated Immune Response.
Zhang L; Li Y; Zhou L; Zhou H; Ye L; Ou T; Hong H; Zheng S; Zhou Z; Wu K; Yan Z; Thiery JP; Cui J; Wu S
Cancer Res; 2023 Jun; 83(11):1834-1850. PubMed ID: 36939388
[TBL] [Abstract][Full Text] [Related]
9. RNA demethylase ALKBH5 promotes colorectal cancer progression by posttranscriptional activation of RAB5A in an m6A-YTHDF2-dependent manner.
Shen D; Lin J; Xie Y; Zhuang Z; Xu G; Peng S; Tang G; Bai L; Zhu M; Zhang Y; Huang Z; Wang P; Liu X; Huang M; Luo Y; Wang X; Yu H
Clin Transl Med; 2023 May; 13(5):e1279. PubMed ID: 37203239
[TBL] [Abstract][Full Text] [Related]
10. N6-methyladenosine reader YTHDF2 promotes multiple myeloma cell proliferation through EGR1/p21
Liu R; Miao J; Jia Y; Kong G; Hong F; Li F; Zhai M; Zhang R; Liu J; Xu X; Wang T; Liu H; Hu J; Yang Y; He A
Oncogene; 2023 May; 42(20):1607-1619. PubMed ID: 37012388
[TBL] [Abstract][Full Text] [Related]
11. YTHDF1 promotes gallbladder cancer progression via post-transcriptional regulation of the m6A/UHRF1 axis.
Chen J; Bai X; Zhang W; Yan Z; Liu Y; Zhou S; Wu X; He X; Yang A
J Cell Mol Med; 2024 May; 28(9):e18328. PubMed ID: 38683130
[TBL] [Abstract][Full Text] [Related]
12. Long non-coding RNA SSTR5-AS1 facilitates gemcitabine resistance via stabilizing NONO in gallbladder carcinoma.
Xue Z; Yang B; Xu Q; Zhu X; Qin G
Biochem Biophys Res Commun; 2020 Feb; 522(4):952-959. PubMed ID: 31810606
[TBL] [Abstract][Full Text] [Related]
13. METTL3-mediated N6-methyladenosine modification of DUSP5 mRNA promotes gallbladder-cancer progression.
Chen HD; Li F; Chen S; Zhong ZH; Gao PF; Gao WZ
Cancer Gene Ther; 2022 Jul; 29(7):1012-1020. PubMed ID: 34799724
[TBL] [Abstract][Full Text] [Related]
14. YTHDF2 promotes the liver cancer stem cell phenotype and cancer metastasis by regulating OCT4 expression via m6A RNA methylation.
Zhang C; Huang S; Zhuang H; Ruan S; Zhou Z; Huang K; Ji F; Ma Z; Hou B; He X
Oncogene; 2020 Jun; 39(23):4507-4518. PubMed ID: 32366907
[TBL] [Abstract][Full Text] [Related]
15. IGF2BP3 promotes progression of gallbladder carcinoma by stabilizing KLK5 mRNA in N
Zhang J; Yang K; Bu J; Yan J; Hu X; Liu K; Gao S; Tang S; Gao L; Chen W
Front Oncol; 2022; 12():1035871. PubMed ID: 36313631
[TBL] [Abstract][Full Text] [Related]
16. METTL3-regulated m6A modification impairs the decidualization of endometrial stromal cells by regulating YTHDF2-mediated degradation of FOXO1 mRNA in endometriosis-related infertility.
Li X; Jin J; Long X; Weng R; Xiong W; Liang J; Liu J; Sun J; Cai X; Zhang L; Liu Y
Reprod Biol Endocrinol; 2023 Oct; 21(1):99. PubMed ID: 37891533
[TBL] [Abstract][Full Text] [Related]
17. YTHDF2 promotes multiple myeloma cell proliferation via STAT5A/MAP2K2/p-ERK axis.
Hua Z; Wei R; Guo M; Lin Z; Yu X; Li X; Gu C; Yang Y
Oncogene; 2022 Mar; 41(10):1482-1491. PubMed ID: 35075244
[TBL] [Abstract][Full Text] [Related]
18. SUMOylation of the m6A reader YTHDF2 by PIAS1 promotes viral RNA decay to restrict EBV replication.
Sugiokto FG; Saiada F; Zhang K; Li R
mBio; 2024 Feb; 15(2):e0316823. PubMed ID: 38236021
[TBL] [Abstract][Full Text] [Related]
19. The RNA m6A Reader YTHDF2 Maintains Oncogene Expression and Is a Targetable Dependency in Glioblastoma Stem Cells.
Dixit D; Prager BC; Gimple RC; Poh HX; Wang Y; Wu Q; Qiu Z; Kidwell RL; Kim LJY; Xie Q; Vitting-Seerup K; Bhargava S; Dong Z; Jiang L; Zhu Z; Hamerlik P; Jaffrey SR; Zhao JC; Wang X; Rich JN
Cancer Discov; 2021 Feb; 11(2):480-499. PubMed ID: 33023892
[TBL] [Abstract][Full Text] [Related]
20. YTHDF2, a protein repressed by miR-145, regulates proliferation, apoptosis, and migration in ovarian cancer cells.
Li J; Wu L; Pei M; Zhang Y
J Ovarian Res; 2020 Sep; 13(1):111. PubMed ID: 32948220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
